Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

739P - Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Endometrial Cancer

Presenters

Whitney Grither

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

W.R. Grither1, M.G. Evans2, R. Ali-Fehmi3, H. Krause4, A. Elliott4, C. Mathews5, M. Oliver6, K. Miller6, S. Wei7, J. Hechtman8, D. Bryant8, M. Oberley9, M.A. Powell1, P.H. Thaker1

Author affiliations

  • 1 Gynecologic Oncology Department, Washington University School of Medicine in St. Louis, 63110 - St. Louis/US
  • 2 Pathology, Caris Life Sciences - Lab & Specimen Receiving, 85040 - Phoenix/US
  • 3 Pathology, University of Michigan, 48109 - Ann Arbor/US
  • 4 Clinical And Translational Research, Caris Life Sciences - Headquarters, 75039 - Irving/US
  • 5 Gynecologic Oncology Department, Women & Infants Hospital - Warren Alpert Medical School of Brown Univ, 02905 - Providence/US
  • 6 Gynecologic Oncology, Women & Infants Hospital - Warren Alpert Medical School of Brown University, 02905 - Providence/US
  • 7 Pathology, Fox Chase Cancer Center - Main Campus, 19111-2497 - Philadelphia/US
  • 8 Pathology, Caris Life Sciences - Headquarters, 75039 - Irving/US
  • 9 Pathology, Caris Life Sciences - Offices & Customer Support, 85040 - Phoenix/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 739P

Background

The DESTINY-PanTumor02 trial demonstrated efficacy of HER2-directed antibody drug conjugates (ADCs) in the treatment of gynecologic malignancies, including EEA. Trial eligibility was determined utilizing HER2 IHC gastric criteria, but many institutions historically use breast criteria for IHC interpretations. As neither scoring system has been validated in gynecologic neoplasms, our study seeks to compare them in EEA.

Methods

Blinded pathology review of HER2 IHC (4B5) from 263 randomly selected EEAs was performed by two board-certified pathologists utilizing gastric and breast criteria. Results of the two scoring systems were compared (Positive [P]: intensity 3+, >10% [breast] or ≥10% [gastric] tumor cell staining, Equivocal [E]: 2+, >10% [breast] or ≥10% [gastric], Low/Negative [N]: >1+, ≤10% [breast] or <10% [gastric], or any percentage of 1+). Tumors were analyzed for ERBB2 copy number amplification by DNA (592-gene or whole exome) sequencing and statistical significance determined using unpaired T-test.

Results

Of HER2 P cases, 96% (49/51) were concordant between breast/gastric criteria, median of 13.0 copies of ERBB2. HER2 E tumors showed a lower rate of concordance with 51% (30/59) concordant cases, median of 2.5 copies of ERBB2. Of discordant HER2 E tumors, 44% (26/59) of E cases were N by breast/E by gastric (1.8 median copies, p < 0.02 vs concordant cases). HER2 N cases were 86% (155/182) concordant (1.9 median copies, p = 0.96 vs N by breast/E by gastric cases).

Conclusions

While gastric and breast criteria demonstrated 96% concordance in identifying EEAs positive for HER2 overexpression, equivocal staining was more often documented with gastric scoring. This greater frequency of equivocal results may suggest a preference for gastric criteria in the assessment of EEA, matching trial inclusion criteria where clinical benefit of HER2 ADCs has been established in patients with HER2 equivocal tumors. Table: 739P

Concordance and discordance of HER2 IHC calls by gastric and breast criteria

IHC Call Gastric
P E N
Breast P 49 1 0
E 1 30 1
N 0 26 155

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M.G. Evans: Financial Interests, Personal, Invited Speaker: Caris Life Sciences; Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. H. Krause: Financial Interests, Institutional, Full or part-time Employment, I am a full time employee at Caris Life Sciences: Caris Life Sciences. A. Elliott: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences. C. Mathews: Financial Interests, Institutional, Research Funding: AstraZeneca, Tesaro/GSK, Astellas Pharma, Seattle Genetics, Deciphera, Moderna, Regeneron, Roche/Genentech, Pfizer, Laekna Therapeutics, EMD Serono, Merck, Genmab, Avenge Bio, Zentalis, ImmunoGen, Elucida Oncology, Artios, Volastra Therapeutics, AADI, Repare Therapeutics. S. Wei: Financial Interests, Personal, Other, board member of molecular tumor board of Caris Life Sciences: Caris Life Sciences. J. Hechtman: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer. D. Bryant: Financial Interests, Institutional, Full or part-time Employment, Senior Medical Director of Pathology: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares, Own stock and have stock options: Caris Life Sciences. M. Oberley: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck, Eisai, AstraZeneca, Seagen, Immunogenicity. P.H. Thaker: Financial Interests, Personal, Advisory Board: Merck, GSK, Seagen, Immunon, ImmunoGen, Novocure, Zentalis; Financial Interests, Personal, Other, consulting: Caris, Verastem; Financial Interests, Personal, Other, DSMB committee: Iovance; Financial Interests, Institutional, Research Grant: Merck, GSK; Financial Interests, Institutional, Coordinating PI: Zentalis, Seagen, ImmunoGen; Financial Interests, Institutional, Local PI: Verastem, Genelux. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.